A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2,Allergy

当前位置： X-MOL 学术 › Allergy › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2
Allergy ( IF 12.4 ) Pub Date : 2021-09-08 , DOI: 10.1111/all.15080
Mona O Mohsen _{1,

2,

3} , Ina Balke ₄ , Simon Zinkhan _{1,

2} , Villija Zeltina ₄ , Xuelan Liu _{1,

2,

5} , Xinyue Chang _{1,

2} , Pascal S Krenger _{1,

2} , Kevin Plattner _{1,

2} , Zahra Gharailoo _{1,

2} , Anne-Cathrine S Vogt _{1,

2} , Gilles Augusto _{1,

2,

6} , Marianne Zwicker _{1,

2} , Salony Roongta _{1,

2} , Dominik A Rothen _{1,

2} , Romano Josi _{1,

2} , Joana J da Costa _{1,

2} , Jan M Sobczak _{1,

2} , Aleksandra Nonic _{1,

2} , Lee-Anne Brand _{1,

2} , Katja Nuss ₇ , Byron Martina _{8,

9} , Daniel E Speiser _{1,

2} , Thomas Kündig ₁₀ , Gary T Jennings ₃ , Senta M Walton ₃ , Monique Vogel _{1,

2} , Andris Zeltins ₄ , Martin F Bachmann _{1,

2}

Affiliation

Department of Rheumatology and Immunology, University Hospital, Bern, Switzerland.
Department of BioMedical Research, University of Bern, Bern, Switzerland.
Saiba AG, Pfaeffikon, Switzerland.
Latvian Biomedical Research & Study Centre, Riga, Latvia.
International Immunology Center, Anhui Agricultural University, Hefei, China.
Nuffield Department of Medicine, Centre for Cellular and Molecular Physiology (CCMP), The Jenner Institute, University of Oxford, Oxford, UK.
Musculoskeletal Research Unit (MSRU), Department of Molecular Mechanisms of Disease (DMMD), Vetsuisse Faculty, University of Zurich (UZH), Zurich, Switzerland.
Erasmus Medical Center, department of Viroscience, Rotterdam, The Netherlands.
Artemis Bio-Support, Delft, The Netherlands.
Department of Dermatology, University Hospital Zurich (USZ), University of Zurich (UZH), Zurich, Switzerland.

SARS-CoV-2 caused one of the most devastating pandemics in the recent history of mankind. Due to various countermeasures, including lock-downs, wearing masks, and increased hygiene, the virus has been controlled in some parts of the world. More recently, the availability of vaccines, based on RNA or adenoviruses, has greatly added to our ability to keep the virus at bay; again, however, in some parts of the world only. While available vaccines are effective, it would be desirable to also have more classical vaccines at hand for the future. Key feature of vaccines for long-term control of SARS-CoV-2 would be inexpensive production at large scale, ability to make multiple booster injections, and long-term stability at 4℃.

中文翻译：

一种针对 SARS-CoV-2 的可扩展且具有高免疫原性的病毒样颗粒疫苗

SARS-CoV-2 引起了人类近代史上最具破坏性的流行病之一。由于采取了各种对策，包括封锁、戴口罩和加强卫生，该病毒已在世界某些地区得到控制。最近，基于 RNA 或腺病毒的疫苗的可用性大大提高了我们抵御病毒的能力。但是，仅在世界某些地区。虽然可用的疫苗是有效的，但未来也希望手头有更多的经典疫苗。用于长期控制 SARS-CoV-2 的疫苗的关键特征是大规模生产成本低、能够进行多次加强注射，以及在 4℃ 下的长期稳定性。

更新日期：2021-09-08

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>